Date: Thursday, June 5, 2014
Time: 10:00 (PDT), 13:00 (EDT), 17:00 (GMT)
This WuXi AppTec event is complementary and open to life science professionals globally.
Please click HERE to register online.
Breakthrough therapies are changing the market for new medicines targeting life-threatening diseases, and redefining R&D strategies from small biotech to large pharmaceutical companies. With the promise to drastically shorten drug development timelines, breakthrough designation (BTD) affords advantages including expedited FDA review, flexibility in IND requirements, and options for smaller clinical trials. In this complimentary live webinar open to life science professional globally, WuXi brings together industry experts to discuss their discovery stories, lessons learned that led to the coveted status of BTD, and their perspectives on how BTD is redefining the R&D landscape.
Speakers/Q&A Panel Click HERE for speaker biography.
Tony Wood SVP and Head of Worldwide Medicinal Chemistry, Pfizer
Michael Sofia President, CSO and Co-Founder, OnCore BioPharma
Christopher Hill VP of Discovery Chemistry, Merck
Richard Soll SVP of International Discovery Service Unit, WuXi AppTec (moderator)
Submit your questions for the speakers in advance during registration. Tweet your questions to us #BreakthroughDrugs.